LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.4095
Abstract: 4095 Background: LEAP-002 was a randomized, double-blind, phase 3 study (NCT03713593) that was conducted to evaluate the efficacy and safety of first-line lenvatinib plus pembrolizumab versus lenvatinib plus placebo in participants with advanced hepatocellular carcinoma… read more here.
Keywords: lenvatinib plus; pembrolizumab versus; plus pembrolizumab; lenvatinib ... See more keywords